Abd El Moumen, M., Ezz El Arab, L., Mosalam, N., Gaballah, A. (2019). Retrospective Analysis of Prognostic Factors in Adult Glioblastoma Multiforme: A Single Institution Experience. Research in Oncology, 15(1), 20-25. doi: 10.21608/resoncol.2019.6360.1071
Mohamed S. Abd El Moumen; Lobna R. Ezz El Arab; Nesreen Mosalam; Ahmed Gaballah. "Retrospective Analysis of Prognostic Factors in Adult Glioblastoma Multiforme: A Single Institution Experience". Research in Oncology, 15, 1, 2019, 20-25. doi: 10.21608/resoncol.2019.6360.1071
Abd El Moumen, M., Ezz El Arab, L., Mosalam, N., Gaballah, A. (2019). 'Retrospective Analysis of Prognostic Factors in Adult Glioblastoma Multiforme: A Single Institution Experience', Research in Oncology, 15(1), pp. 20-25. doi: 10.21608/resoncol.2019.6360.1071
Abd El Moumen, M., Ezz El Arab, L., Mosalam, N., Gaballah, A. Retrospective Analysis of Prognostic Factors in Adult Glioblastoma Multiforme: A Single Institution Experience. Research in Oncology, 2019; 15(1): 20-25. doi: 10.21608/resoncol.2019.6360.1071
Retrospective Analysis of Prognostic Factors in Adult Glioblastoma Multiforme: A Single Institution Experience
1Oncology Department, Galaa Military Hospital, Cairo, Egypt
2Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
Abstract
Background: Primary brain tumors represent 2% of cancers in adults. Glioblastoma Multiforme (GBM) is the most frequent among these tumors. Different prognostic factors have been identified including age, performance status, extent of surgery and genetic factors. Aim: To analyze treatment outcome and prognostic factors in adult patients with GBM treated at a single institution. Methods: We retrospectively collected the data of patients treated for GBM form January 2012 till December 2016. During this 5-years period, 111 patients were identified and the data of 93(84%) of them was complete and included in the analysis. Results: Males represented 67% of patients, their median age was 52 years and the Eastern Cooperative Oncology Group (ECOG) performance status was 1, 2 and 3 in 48%, 40% and 12% respectively. Only 4.3% of patients underwent complete surgical resection, 38% underwent partial resection and 58% underwent biopsy. Post-operative treatment was radiotherapy alone in 30% of patients and chemo-radiotherapy in 70%. The median progression-free survival (PFS) and overall survival (OS) were 8 months (95% Confidence Interval: 6.678-9.322) and 10 months (95% Confidence Interval: 7.522-12.487), respectively. Longer PFS was associated with age Conclusion: Glioblastoma Multiforme remains an aggressive disease with high mortality rate and poor outcome. Complete resection and adjuvant chemo-radiotherapy improve PFS and OS.
View on SCiNiTO
Top